Loading...

Dicerna Pharmaceuticals, Inc.

DRNA•NASDAQ
Healthcare
Biotechnology
$38.22
$0.00(0.00%)

Dicerna Pharmaceuticals, Inc. (DRNA) Stock Overview

Explore Dicerna Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.0/100

Key Financials

Market Cap0
P/E Ratio-25.26
EPS (TTM)N/A
ROE-0.78%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 Month$41.44
3 Months$49.53
1 Year Target$22.03

DRNA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Dicerna Pharmaceuticals, Inc. (DRNA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 0.00, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $22.03.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -25.26 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

0.00RSI (14)
0.00MACD
0.00ADX
Stats data is not available for DRNAStats details for DRNA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for DRNAAnalyst Recommendations details for DRNA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

CEO

Douglas Fambrough

Employees

302

Headquarters

33 HAYDEN AVENUE, Lexington, MA

Founded

2014

Frequently Asked Questions

;